Millennium/Sanofi discontinue CCR1 inhibitor for RA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
After a Phase II study of MLN3897 failed to meet pre-established criteria to justify moving into Phase III, Millennium and partner Sanofi-Aventis are discontinuing development of the CCR1 inhibitor in rheumatoid arthritis, Millennium CEO Deborah Dunsire tells a Piper Jaffray conference Nov. 28. MLN3897 showed no safety signals, she noted, but observed that "when you're going into a very competitive marketplace, which is what RA is, I think you need to be very disciplined about delivering strong incremental value because the Phase III investment is so gigantic, as well as the marketing investment"...